Search results
Showing 1 to 15 of 49 results for oxaliplatin
Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer (TA100)
Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer in adults.
Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Evidence-based recommendations on aflibercept (Zaltrap) with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer after oxaliplatin-based chemotherapy in adults.
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
In development Reference number: GID-TA11468 Expected publication date: 14 May 2026
In development Reference number: GID-TA11823 Expected publication date: TBC
NICE is unable to make a recommendation on pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1052
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Oesophago-gastric cancer: assessment and management in adults (NG83)
This guideline covers assessing and managing oesophago-gastric cancer in adults, including radical and palliative treatment and nutritional support. It aims to reduce variation in practice through better organisation of care and support, and improve quality of life and survival by giving advice on the most suitable treatments depending on cancer type, stage and location.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.